Abivax Announces Closing of $747.5 Million Public Offering
1. Abivax closed a $747.5 million public offering. 2. Net proceeds of approximately $700.3 million will support operations until Q4 2027. 3. Funds are aimed at the NDA submission for Ulcerative Colitis. 4. Lead drug candidate, obefazimod, is in Phase 3 for ulcerative colitis treatment.